Zhejiang Bossan Pharma out-licensed global ex-China rights for its innovative novel epidermal growth factor receptor (EGFR) inhibitor to CBT Pharma of California. CBT plans to test two of its own candidates -- a c-Met inhibitor and an anti-PD1 antibody -- together with the Bossan EGFR inhibitor, which is currently in a Phase I China trial. CBT has already partnered
Share this with colleagues:
Original Article: Zhejiang Bossan Out-Licenses Ex-China Rights for EGFR Drug to CBT Pharma